- Q1 2024 BioArctic AB Earnings Call TranscriptMay 17, 2024kr230.2 (-0.78%)Earnings
- Q4 2023 BioArctic AB Earnings Call TranscriptFeb 14, 2024kr217.2 (+8.17%)Earnings
- Q3 2023 BioArctic AB Earnings Call TranscriptNov 08, 2023kr213 (-1.75%)Earnings
- Q2 2023 BioArctic AB Earnings Call TranscriptJul 12, 2023kr291.4 (+0.48%)Earnings
- Q1 2023 BioArctic AB Earnings Call TranscriptApr 27, 2023kr254 (+8.55%)Earnings
- Q4 2022 BioArctic AB Earnings Call TranscriptFeb 03, 2023kr297.4 (-1.78%)Earnings
- Q3 2022 BioArctic AB Earnings Call TranscriptOct 20, 2022kr250 (+4.60%)Earnings
- Q2 2022 BioArctic AB Earnings Call TranscriptJul 12, 2022kr78.35 (-3.15%)Earnings
- Q1 2022 BioArctic AB Earnings Call TranscriptApr 28, 2022kr74.3 (-6.54%)Earnings
- Q4 2021 BioArctic AB Earnings Call TranscriptFeb 03, 2022kr110.2 (-1.25%)Earnings
- Q3 2021 BioArctic AB Earnings Call TranscriptOct 21, 2021kr143.8 (-1.64%)Earnings
- Q2 2021 BioArctic AB Earnings Call TranscriptJul 09, 2021kr145.2 (+4.91%)Earnings
- Q1 2021 BioArctic AB Earnings Call TranscriptApr 21, 2021kr92.6 (+2.66%)Earnings
- Full Year 2020 BioArctic AB Earnings Call TranscriptFeb 04, 2021kr99.8 (-0.70%)Earnings
- Nine Months 2020 BioArctic AB Earnings Call TranscriptOct 14, 2020kr88.45 (+1.43%)Earnings
- Q2 2020 BioArctic AB Earnings Call TranscriptJul 10, 2020kr80.55 (+7.69%)Earnings
- Q1 2020 BioArctic AB Earnings Call TranscriptApr 22, 2020kr64.4 (-7.07%)Earnings
- Full Year 2019 BioArctic AB Earnings Call TranscriptFeb 06, 2020kr82.65 (-3.22%)Earnings
- Q3 2019 BioArctic AB Earnings Call TranscriptOct 24, 2019kr92.5 (+1.82%)Earnings
- Q2 2019 BioArctic AB Earnings Call TranscriptJul 11, 2019kr71.7 (-0.42%)Earnings
- Q1 2019 BioArctic AB Earnings Call TranscriptMay 09, 2019kr75.5 (+0.47%)Earnings
- Full Year 2018 BioArctic AB Earnings Call TranscriptFeb 14, 2019kr97.75 (+2.79%)Earnings
Q1 2021 BioArctic AB Earnings Call Transcript
Welcome to the BioArctic Q1 Report 2021. Today, I am pleased to present CEO, Gunilla Osswald and CFO, Jan Mattsson. (Operator Instructions) Speakers, please begin.
()-
So welcome to BioArctic's First Quarter Report 2021. I'm Gunilla Osswald, and I'm the CEO of BioArctic. I will share the presentation here today with our CFO, Jan Mattsson.
This year has started really well for BioArctic. Our most advanced program, lecanemab, BAN2401, in Alzheimer's disease, has further been strengthened by new data and other data in the Alzheimer's field. Our partner, Eisai, has completed enrollment of patients into the pivotal Clarity AD study. And our Phase IIb results have been published.
Our project portfolio has progressed well and expanded during the first quarter of this year, and I will describe more about this in the presentation here today.
Next slide, please. BioArctic is listed on Nasdaq Stockholm Mid-Cap, and this is our disclaimer.
Next slide, please.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)